{"entity":{"id":"relcobatinib","kind":"drug","name":"Relcobatinib","aka":["ELVN-001"],"tldr":"Relcobatinib is an experimental oral small-molecule kinase inhibitor from Enliven Therapeutics, in phase 1 trials for chronic myeloid leukaemia.","summary":"Relcobatinib (ELVN-001) is an oral small-molecule kinase inhibitor (ATP-competitive) from Enliven Therapeutics. A highly selective ATP-competitive BCR::ABL1 inhibitor that binds a P-loop \"folded-in\" active conformation of ABL1; designed to avoid off-target activity and to cover mutations that cause resistance to allosteric inhibitors such as asciminib. Its furthest stage is phase 1, for chronic myeloid leukaemia. ClinicalTrials.gov registers it in 3 studies linked below. Phase 1 ENABLE recruiting (NCT05304377, NCT06787144); phase 3 ENABLE-2 versus investigator-selected TKI (NCT07905183) registered, not yet recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Enliven Therapeutics: enliventherapeutics.com","url":"https://www.enliventherapeutics.com/pipeline"},{"label":"Enliven Therapeutics: enliventherapeutics.com","url":"https://www.enliventherapeutics.com/pipeline"},{"label":"ClinicalTrials.gov: trials of ELVN-001","url":"https://clinicaltrials.gov/search?intr=ELVN-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["bcr-abl"],"drugs":[],"companies":["enliven-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05304377","nct06787144","nct07905183"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ELVN-001","modality":"Oral small-molecule kinase inhibitor (ATP-competitive)","mechanism":"A highly selective ATP-competitive BCR::ABL1 inhibitor that binds a P-loop \"folded-in\" active conformation of ABL1; designed to avoid off-target activity and to cover mutations that cause resistance to allosteric inhibitors such as asciminib.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/relcobatinib/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/"}],"company":[{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/"}],"trial":[{"id":"nct05304377","kind":"trial","name":"A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia","route":"/trials/nct05304377/"},{"id":"nct07905183","kind":"trial","name":"A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs","route":"/trials/nct07905183/"},{"id":"nct06787144","kind":"trial","name":"ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants","route":"/trials/nct06787144/"}]}}